The Appropriateness of Concomitant Immunomodulators With Anti–Tumor Necrosis Factor Agents for Crohn's Disease: One Size Does Not Fit All
Gil Melmed, Corey A. Siegel(Dartmouth–Hitchcock Medical Center), Shane Devlin, Gilaad G. Kaplan(University of Calgary), Peter M. Irving(Guy's and St Thomas' NHS Foundation Trust), Laura Harrell(University of Chicago), Brennan Spiegel(Cedars-Sinai Medical Center), Patricia Kozuch(Thomas Jefferson University), Adam S. Cheifetz(Beth Israel Deaconess Medical Center), Brian Bressler(University of British Columbia), Jennifer Jones(Dalhousie University), Miles Sparrow(Alfred Health), Leonard Baidoo(University of Pittsburgh Medical Center), Fernando Velayos(Kaiser Permanente San Francisco Medical Center)
Cited by 50
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
ACG Clinical Guideline: Ulcerative Colitis in Adults
|The American Journal of Gastroenterology|2019|1.6k